-
Measuring What Matters: Health-Related Quality of Life in Malaysian Alzheimer's Patients
Sep 9, 2025, 16:22 PM -
Budget Impact of Nivolumab Plus Ipilimumab Plus Chemotherapy as First-Line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer in Switzerland
Sep 9, 2025, 16:22 PM -
KRAS Alterations in Advanced Non-Small Cell Lung Cancer (NSCLC): Temporal Trends in Testing Patterns and Targeted Treatment Use Across Europe Between 2018 and 2024
Sep 9, 2025, 16:22 PM -
Gaps in Cancer Screening Uptake in Ireland: Trends, Barriers and Policy Implications
Sep 9, 2025, 16:22 PM -
Using a Large Language Model (LLM) for Data Extraction of Studies: Learnings From a Targeted Literature Review (TLR) in Non-Small Cell Lung Cancer (NSCLC)
Sep 9, 2025, 16:22 PM -
Lung-Cancer Diagnostic Trajectories: A Nationwide Process-Mining Cluster Analysis of 18,569 French Patients
Sep 9, 2025, 16:22 PM -
Comparing Clinical Benefit Criteria in Health Technology Assessment of Oncology Drugs in the Netherlands and Europe: Driving Real Value or Inequal Access?
Sep 9, 2025, 16:22 PM -
What Makes a Medicine Innovative? A Literature Review of Evaluation Frameworks
Sep 9, 2025, 16:22 PM -
Model Behavior: A Health Economics Checklist for Sales Models
Sep 9, 2025, 16:22 PM -
Integrating Mendelian Randomization With Real-World Evidence: Cost-Effectiveness of Lipoprotein Testing for Primary Prevention of Cardiovascular Disease in High-Income Countries
Sep 9, 2025, 16:22 PM -
Fezolinetant Veoza™ As a Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms in Postmenopausal Women: A Systematic Literature Review and Meta-Analysis
Sep 9, 2025, 16:22 PM -
Trends and Scope of Japan’s Across-the-Board Pharmaceutical Price Revisions in FY2021-25
Sep 9, 2025, 16:22 PM -
Regulatory Approval and Economic Evaluation of Tumor-Agnostic Therapies: A Comparative Study of Larotrectinib and Entrectinib
Sep 9, 2025, 16:22 PM -
Drivers of Inpatient Costs in Oncology Patients Undergoing Major Abdominal Surgery: Evidence from a Middle-Income Country
Sep 9, 2025, 16:22 PM -
Recognizing the Full Value of Novel Antibiotics: Identifying Value Elements in the Context of Antimicrobial Resistance
Sep 9, 2025, 16:22 PM -
Evaluating the Economic Value of First-Line (1L) Treatment Strategies for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Insights From the Portuguese Healthcare System
Sep 9, 2025, 16:22 PM -
The PAVING II Interview Study: Assessing Evolving Patient Preferences Regarding Gene Therapy for Hemophilia Patients
Sep 9, 2025, 16:22 PM -
Agentic-AI Analyzer to Chat With Your Excel-Based Cost-Effectiveness Models
Sep 9, 2025, 16:22 PM -
Economic and Antibiotic Benefits of Vonoprazan-Based Regimens for First-Line Helicobacter Pylori Eradication in China
Sep 9, 2025, 16:22 PM -
From Clinic to Cohort: The VOICE Vitiligo Registry and Bioresource as a Blueprint for High-Fidelity Specialist Registries
Sep 9, 2025, 16:22 PM